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Effect of 10-valent pneumococcal conjugate vaccine on the
incidence of radiologically-confirmed pneumonia and
clinically-defined pneumonia in Kenyan children:
an interrupted time-series analysis
Micah Silaba, Michael Ooko, Christian Bottomley, Joyce Sande, Rachel Benamore, Kate Park, James Ignas, Kathryn Maitland, Neema Mturi,
Anne Makumi, Mark Otiende, Stanley Kagwanja, Sylvester Safari, Victor Ochola, Tahreni Bwanaali, Evasius Bauni, Fergus Gleeson,
Maria Deloria Knoll, Ifedayo Adetifa, Kevin Marsh, Thomas N Williams, Tatu Kamau, Shahnaaz Sharif, Orin S Levine, Laura L Hammitt,
J Anthony G Scott

Summary

Background Pneumococcal conjugate vaccines (PCV) are highly protective against invasive pneumococcal disease
caused by vaccine serotypes, but the burden of pneumococcal disease in low-income and middle-income countries is
dominated by pneumonia, most of which is non-bacteraemic. We examined the effect of 10-valent PCV on the
incidence of pneumonia in Kenya.
Methods We linked prospective hospital surveillance for clinically-defined WHO severe or very severe pneumonia at
Kilifi County Hospital, Kenya, from 2002 to 2015, to population surveillance at Kilifi Health and Demographic
Surveillance System, comprising 45 000 children younger than 5 years. Chest radiographs were read according to a
WHO standard. A 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10)
was introduced in Kenya in January, 2011. In Kilifi, there was a three-dose catch-up campaign for infants (aged <1 year)
and a two-dose catch-up campaign for children aged 1–4 years, between January and March, 2011. We estimated the
effect of PCV10 on the incidence of clinically-defined and radiologically-confirmed pneumonia through interrupted
time-series analysis, accounting for seasonal and temporal trends.
Findings Between May 1, 2002 and March 31, 2015, 44 771 children aged 2–143 months were admitted to Kilifi County
Hospital. We excluded 810 admissions between January and March, 2011, and 182 admissions during nurses’ strikes.
In 2002–03, the incidence of admission with clinically-defined pneumonia was 2170 per 100 000 in children aged
2–59 months. By the end of the catch-up campaign in 2011, 4997 (61·1%) of 8181 children aged 2–11 months had
received at least two doses of PCV10 and 23 298 (62·3%) of 37 416 children aged 12–59 months had received at least
one dose. Across the 13 years of surveillance, the incidence of clinically-defined pneumonia declined by 0·5%
per month, independent of vaccine introduction. There was no secular trend in the incidence of radiologicallyconfirmed pneumonia over 8 years of study. After adjustment for secular trend and season, incidence rate ratios for
admission with radiologically-confirmed pneumonia, clinically-defined pneumonia, and diarrhoea (control condition),
associated temporally with PCV10 introduction and the catch-up campaign, were 0·52 (95% CI 0·32–0·86), 0·73
(0·54–0·97), and 0·63 (0·31–1·26), respectively. Immediately before PCV10 was introduced, the annual incidence of
clinically-defined pneumonia was 1220 per 100 000; this value was reduced by 329 per 100 000 at the point of PCV10
introduction.
Interpretation Over 13 years, admissions to Kilifi County Hospital for clinically-defined pneumonia decreased sharply
(by 27%) in association with the introduction of PCV10, as did the incidence of radiologically-confirmed pneumonia
(by 48%). The burden of hospital admissions for childhood pneumonia in Kilifi, Kenya, has been reduced substantially
by the introduction of PCV10.
Funding Gavi, The Vaccine Alliance and Wellcome Trust.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
After the neonatal period, pneumonia is the greatest cause
of death in children younger than 5 years1 and, before
the intro
duction of pneumococcal conjugate vaccines
(PCVs), the most common cause of fatal pneumonia was
Streptococcus pneumoniae (pneumococcus).2 PCVs are
www.thelancet.com/lancetgh Vol 7 March 2019

highly efficacious against invasive pneumococcal disease
caused by vaccine serotypes and their introduction in
high-income countries has decreased transmission of
vaccine serotypes and reduced invasive pneumococcal
disease among vaccinated and unvaccinated populations.
However, invasive pneumococcal disease represents only
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Research in context
Evidence before this study
We searched PubMed for articles published between inception
and Sept 1, 2018, using the MeSH keywords: “pneumonia,
pneumococcal/prevention and control” AND “vaccines,
conjugate” AND (“child” OR “infant”) AND (“South America” OR
“central America” OR “Asia”, western” OR “Asia, southeastern” OR
“Africa, south of the Sahara”), with no language restrictions.
Our search showed that three randomised controlled trials of
pneumococcal conjugate vaccines (PCVs) among children aged
0–2 years old in low-income and middle-income countries have
examined radiologically-confirmed pneumonia as an endpoint.
The efficacy of a 9-valent PCV was 37% (95% CI 25–48) in
The Gambia, and 20% (2–35) in South Africa among HIV
uninfected children. In the Philippines, the 95% CI for vaccine
efficacy of an 11-valent PCV was –1% to 41% with a point
estimate of 23%. Against clinically-defined severe pneumonia,
PCV9 had an efficacy estimate of 17% (4–27) in South Africa
(HIV uninfected) and 12% (–9 to 29) in The Gambia. PCV11 was
not protective against severe pneumonia in the Philippines.
These trials do not capture herd protection, which is a strong
feature of the use of PCV in practice, or the effect on older
children aged 2–4 years. The introduction of PCV7 in the USA
caused a 39% reduction in admissions to hospital for pneumonia
among children younger than 2 years; however, in low-income
and middle-income countries, the magnitude of the effect is less
clear. In The Gambia, the introduction of PCV7/PCV13 led to a
24–31% reduction in radiologically-confirmed pneumonia,
but the effect on clinically-defined pneumonia was 5–15%,
dependent on age. A retrospective case-review study of
admission to hospital with pneumonia in Rwanda estimated

a small fraction of the burden of pneumococcal disease.
For example, in a randomised controlled trial3 of 9-valent
PCV (PCV9) in The Gambia, 15 cases of radiologicallyconfirmed pneumonia were prevented for every two cases
of invasive pneumococcal disease.
In low-income and middle-income countries, the
efficacy of PCV against clinically-defined pneumonia is
lower (0–17%) than the efficacy against invasive pneumo
coccal disease or radiologically-confirmed pneumonia.3–5
This finding suggests that clinically-defined pneumonia
as an endpoint has poor specificity for pneumococcal
pneumonia. WHO developed a set of interpretive criteria
and procedures to standardise the reading of paediatric
chest radiographs in pneumonia cases,6,7 which defined
an endpoint that has increased specificity for pneu
mococcal pneumonia and commensurately increased
estimates of vaccine efficacy (20–37%).3,4,8,9
Longitudinal studies of disease incidence, with an
interrupted time-series analysis, are likely to capture
the beneficial effects of herd protection due to reduced
transmission of vaccine-serotype pneumococci and the
effects of direct vaccine protection. These studies are also
sensitive to serotype replacement disease if infection
e338

that vaccine effectiveness of PCV7 was as high as 54%.
A randomised controlled trial of 10-valent PCV, done in
Argentina, Colombia and Panama, showed a vaccine efficacy
against radiologically-confirmed pneumonia of 25·7%.
Added value of this study
This study, with its long time-span, consistency of methods,
and rapid introduction of vaccination to children younger than
5 years with a catch-up campaign, provides robust evidence of
the effect of PCV on pneumonia in tropical Africa. It is the
first study to show the effect of PCV10 in a low-income setting.
The introduction of PCV10 was associated with a reduction in
admissions to hospital with clinically-defined pneumonia
of 27% and with radiologically-confirmed pneumonia of 48%,
among children aged 2–59 months. These effects are larger
than those seen in randomised controlled trials, and are
compatible with the development of herd protection. Our
findings show that Streptococcus pneumoniae was responsible
for at least 27% of all admissions to hospital with pneumonia in
the pre-vaccine era and that the introduction of PCV10 has led
to a substantial decline in childhood morbidity in Kenya and in
the burden of hospital admissions.
Implications of all the available evidence
Pneumonia is the greatest cause of child death outside the
neonatal period. It is also the most common manifestation of
pneumococcal disease and, therefore, is the strongest driver of
vaccine cost-effectiveness analyses. The evidence of a substantial
effect of PCV10 against pneumonia will underpin policy making
in African countries as they confront the challenge of sustaining
PCV programmes independently from Gavi.

with non-vaccine serotypes leads to pneumonia. To
date, there have been only two field studies of PCV
effectiveness against pneumonia in low-income settings;
one study10 had just 2 years of pre-vaccine surveillance,
the other had none.11
In the USA, the effect of PCV7 on routine hospital
admissions with all-cause pneumonia was estimated,
using interrupted time-series analysis, to be a
39% reduction in children younger than 2 years, which
is substantially greater than the efficacy estimates
against clinically-defined pneumonia or radiologicallyconfirmed pneumonia in a randomised controlled
trial.12–14 Unfortunately, in most low-income settings,
the quality of routine administrative hospital data is
insufficient for evaluation with this study design.
In an interrupted time-series analysis, after adjusting
for seasonal and temporal trends in pneumonia hospital
isation, the residual change in incidence associated
with vaccine introduction is as robust an estimate of
vaccine impact as is possible in a non-randomised
design.15,16 Here, we aimed to use this method to capture
the effect of PCV10 on clinically-defined and radio
logically-confirmed pneumonia in a unique clinical and
www.thelancet.com/lancetgh Vol 7 March 2019

Articles

demographic surveillance platform in Kenya with realtime monitoring of vaccine coverage.17,18 We introduced
PCV10 with a catch-up campaign for children younger
than 5 years to increase temporal specificity of the timeseries effect.

Methods

Study design and participants
We studied residents (aged ≥2 months to <12 years) of
the Kilifi Health and Demographic Surveillance System
(KHDSS). KHDSS has monitored births, deaths, and
migration events in a population of 280 000 through
4-monthly household visits since 2001.18
Kilifi County Hospital (Kilifi, Kenya) is centrally located
within KHDSS and is the only paediatric inpatient facility
in the study area. It has 55 paediatric beds. Since 2002,
all admissions have been recorded using a standard
electronic clinical record linked to the KHDSS population
register.
We used WHO definitions of clinical pneumonia
applicable at the start of the surveillance based on
presentation with cough or difficulty breathing.19 Those
with lower chest-wall indrawing but no danger signs
had an admission diagnosis of severe pneumonia; those
with at least one danger sign had very severe pneumonia.
Danger signs were central cyanosis, inability to drink,
convulsions, lethargy, prostration, unconsciousness, or
head nodding.19 Since there were no specific definitions
for children aged 5–11 years, we applied the same
criteria as for younger children. Children with nonsevere pneumonia are not normally admitted and were
not included in the surveillance. Admission to hospital
with diarrhoea was the control condition. Diarrhoea was
defined as at least three loose stools in the past 24 hours.
From April, 2006 onwards, children with WHO-defined
severe or very severe pneumonia were investigated,
whenever possible, with a single frontal chest radiograph.
Presentation with convulsions or lethargy alone, without
other signs of pneumonia, was not considered by the
local ethical review committee to be sufficient justification
for investigation with a chest radiograph.
Written informed consent was obtained from the
parents or guardians of all participants in the study. The
study was approved by the KEMRI National Ethical
Review Committee and Oxford Tropical Research Ethics
Committee.

Radiological reading and interpretation
Chest radiographs were taken with a Philips Cosmos-BS
machine throughout the study period. A Philips Practix
360 portable machine became available in March, 2012.
The radiology system was digitised in August, 2011;
thereafter, a Philips PCR Eleva-S was used to process digi
tal cassettes (10 × 12 inches; 1670 × 2010 pixels). Archived
film images were digitised using a Vidar Pro Advantage
digitiser. Images were encoded using Hipax software into
DICOM format at 150 dpi and 12 bits. All images were
www.thelancet.com/lancetgh Vol 7 March 2019

cropped to de-identify patients and remove peripheral
clues about the radiological method used, before being
distributed in JPEG format in batches of 100 selected at
random from pre-vaccine and post-vaccine introduction
images.
Radiological interpretation followed the standard de
fined by WHO for the identification of primary endpoint
pneumonia, which was used in the phase 3 trials of
PCVs.6,7 We categorised images by quality: adequate,
suboptimal, or uninterpretable. Uninterpretable images
were not assigned a diagnosis. Primary endpoint pneu
monia was defined by the presence of consolidation or
pleural effusion, or both.
Each image was read independently by two primary
readers: a consultant radiologist and a trainee paediatrician
in Kenya.20 All images with discordant interpretations, and
13% of those with agreement (as per our previous work20),
were referred to three consultant radiologists in Oxford,
UK, who arbitrated the readings. Concordant readings of
the primary readers were considered final.

Vaccine introduction and monitoring
In January, 2011, a 10-valent PCV (Synflorix; Glaxo
SmithKline Biologicals, Rixensart, Belgium), consisting
of capsular polysaccharides of serotypes 1, 4, 5, 6B, 7F,
9V, 14, 18C, 19F, and 23F conjugated to either nontypeable Haemophilus influenzae (NTHi) protein D,
diphtheria, or tetanus toxoid, was introduced in Kenya
in three doses at weeks 6, 10, and 14. There was a
three-dose catch-up campaign for infants during 2011.
In addition, in Kilifi County, children aged 12–59 months
were offered two doses of vaccine via campaigns on
Jan 31 to Feb 6, 2011, and March 21–27, 2011.
Haemophilus influenzae type b conjugate vaccine was
introduced in Kenya in 2001. Rotavirus vaccine (Rotarix;
GlaxoSmithKline Biologicals) was introduced, without a
catch-up campaign, in July, 2014.
Vaccine surveillance was established in April, 2009,
in 26 vaccine clinics serving KDHSS.17 Data clerks recorded
all immunisations given against the identity of the child in
the KHDSS population register at the point of vaccination.
However, during the catch-up campaign, vaccinations
were recorded against lists of KHDSS residents.

Statistical analysis
The incidence of admission to hospital with clinicallydefined pneumonia or diarrhoea was calculated for each
month between May, 2002, and March, 2015. Children
who had both pneumonia and diarrhoea were classified
as having pneumonia alone. The monthly incidence
of radiologically-confirmed pneumonia was calculated
between April, 2006, and March, 2014. Mid-month
population counts from the KHDSS were used to
estimate child years at risk in each month.
We fitted linear regression models to log-transformed
monthly rates of radiologically-confirmed and clinicallydefined pneumonia to estimate the effect of PCV10.
e339
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2002*

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015†

Population size (person-years)
2–11 months

4414

6789

6837

7103

7830

7385

7533

8047

7152

8058

7604

7401

7930

12–23 months

5087

7834

8894

8657

8745

9565

9114

9649

9927

8854

9954

9269

9178

1891
2435

24–59 months

15 686

23 805

24 731

25 485

25 738

26 137

26 568

27 042

28 200

28 463

28 263

28 684

27 835

6951

60–143 months

29 979

45 552

47 917

50 617

52 259

53 579

55 064

56 339

57 439

58 899

59 605

61 052

62 596

15 604

Vaccinated with PCV (%)‡
2–11 months (≥2 doses)

··

··

··

··

··

··

··

··

··

79·9

76·4

81·4

87·7

12–23 months (≥1 dose)

··

··

··

··

··

··

··

··

··

76·0

84·4

85·6

89·3

84·2
91·6

24–59 months (≥1 dose)

··

··

··

··

··

··

··

··

··

62·7

66·9

74·6

82·8

86·5

60–143 months (≥1 dose)

··

··

··

··

··

··

··

··

··

7·2

15·7

24·1

32·4

42·8

Admission to hospital
All causes
2–59 months

1131

2463

2315

1870

2006

1703

1578

1724

1455

869

1040

646

1049

257

60–143 months

208

389

359

393

404

348

342

376

418

294

307

252

448

139

167

420

521

443

535

382

321

334

330

154

213

97

145

49

20

34

41

36

35

26

18

18

28

15

9

10

13

3

263

463

445

264

277

306

273

321

281

140

209

142

230

40

25

45

36

28

41

30

23

28

43

14

23

30

43

8

130

413

480

348

422

301

283

427

218

203

145

86

132

8

8

17

19

19

16

16

11

33

26

7

15

5

12

2

2–59 months

609

1,166

765

480

391

231

184

112

193

145

134

91

221

62

60–143 months

109

188

106

94

106

54

38

36

83

84

84

83

155

53

169

411

431

345

393

263

254

335

235

152

153

115

160

39

34

48

61

58

59

40

39

59

56

23

57

26

50

17

Severe pneumonia
2–59 months
60–143 months
Very severe pneumonia
2–59 months
60–143 months
Diarrhoea§
2–59 months
60–143 months
Positive malaria slide

Severe undernutrition¶
2–59 months
60–143 months

Months of pneumonia observation in the study
Clinically defined

8

12

12

12

12

12

12

12

12

9

11

11

12

3

Radiologically confirmed

0

0

0

0

9

12

12

12

12

9

11

11

3

0

Number of pneumonia admissions with radiographs obtained
2–59 months

··

··

··

··

332

401

360

281

253

185

310

163

57

··

60–143 months

··

··

··

··

25

26

19

18

17

12

13

29

5

··

Number of admissions with radiologically-confirmed pneumonia
2–59 months

··

··

··

··

76

94

70

68

65

28

46

49

21

··

60–143 months

··

··

··

··

11

6

6

6

6

4

5

8

3

··

Population estimates are mid-year populations. In 2002 and 2015, these are multiplied by the proportion of the year under observation. PCV=pneumococcal conjugate vaccine. *2002 includes only
May to December. †2015 includes only January to March. ‡Vaccine coverages are estimated in the last week of each year except 2015 (last week of March 2015). §Of 5229 patients with diarrhoea, 1427 also had
clinically-defined pneumonia were classified only as pneumonia. ¶Severe undernutrition was defined as a weight-for-age Z score of less than –3 on admission to hospital.

Table 1: Demographics of population under observation within the Kilifi Health and Demographic Surveillance System

See Online for appendix
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The models included a period effect (pre-PCV10 vs postPCV10), monthly time trend, and seasonality, which was
modelled using the month of the year. Differences in
the time trends before and after vaccination were tested
through the inclusion of an interaction term. We
modelled the error as an autoregressive moving average
process, using Aikake’s information criterion and plots
of the autocorrelation function of residuals to choose
the order of the process.21 After observing the results of
the analysis of the control condition, we further analysed
the effect of PCV10 on clinically-defined pneumonia by

adjusting for monthly incidence of diarrhoea
admissions, instead of time in months. Because of the
opposite pattern of seasonal incidence for diarrhoea and
clinically-defined pneumonia (appendix), we desea
sonalised the log-diarrhoea series by subtracting trendadjusted estimates for the effect of each month. We
smoothed the data using locally weighted scatterplot
smoothing.
We excluded January to March, 2011, as a transition
period during which PCV10 was introduced among
children younger than 5 years. We also excluded
www.thelancet.com/lancetgh Vol 7 March 2019
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admissions in December, 2012, and December, 2013,
because of nurses’ strikes.
When radiographs were not obtained, we used multiple
imputations based on information on admission year,
month of admission, sex, age, HIV status, malaria slide
positivity, pneumonia severity, outcome of hospital
admission (alive at discharge or died), referral, and day of
the week when the patient was admitted. We created
20 imputed datasets, via chained equations,22,23 and used
Rubin’s rules to combine estimates across the imputed
datasets.
We calculated vaccine effectiveness as 1 – incidence
rate ratio (IRR) using the IRRs estimated from the re
gression model for each disease classification. We
estimated the absolute reduction in admission rates by
multiplying the vaccine effectiveness estimates against
the model predictions of incidence in the month
immediately before the introduction of PCV10 in
December, 2010. All statistical analyses were using
STATA software (version 14).

Role of the funding source
The funders of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to all
the data in the study and had final responsibility for the
decision to submit for publication.

Results
In May, 2002, there were 37 556 residents in KHDSS
aged 2–59 months and 44 672 residents aged
60–143 months. By March, 2015, these figures were 45 601
and 62 502, respectively. By March 31, 2011, 4997 (61·1%) of
8181 children aged 2–11 months had received at least
two doses of PCV10 and 23298 (62·3%) of 37416 children
aged 12–59 months had received at least one dose of
PCV10. Coverage increased throughout the rest of the
study period (table 1).
Between May 1, 2002, and March 31, 2015,
44 771 children aged 2–143 months were admitted to
Kilifi County Hospital (table 1). We excluded
810 ad
missions during the PCV10 introduction and
catch-up campaign period (between January, 2011, and
March, 2011), and 182 admissions during nurses’ strikes.
Of the remaining 43 779 admissions, 24 783 (57%) were
residents of KHDSS (figure 1); of these, 8488 (34%) had
severe or very severe clinically-defined pneumonia.
Throughout the 13-year study period, the number of
admissions to hospital among KHDSS residents aged
2–59 months fell progressively, particularly those with
severe undernutrition (defined as weight for age Z score
less than –3) and a positive malaria slide (table 1). The
prevalence of HIV infection among mothers attending
the antenatal clinic in Kilifi County Hospital was 4·1% in
2005–07, 4·2% in 2008–10, and 2·7% in 2011–15.
Among pneumonia patients, 4522 (53%) were admitted
during the radiological study period (April, 2006, to
www.thelancet.com/lancetgh Vol 7 March 2019

44 771 admissions (aged 2–143 months) to hospital between May, 2002, and
March, 2015

992 excluded
72 nurses strike December, 2012
110 nurses strike December, 2013
810 PCV10 rollout period

43 779 analysed

18 996 non-residents excluded

24 783 residents in the Kilifi Health and Demographic Surveillance System

16 295 other clinical diagnoses excluded

8488 with severe or very severe pneumonia

3966 not within the X-ray study period
3528 May, 2002, to March, 2006
438 April, 2014, to March, 2015

4522 within the X-ray study period (April, 2006, to March, 2014)

2016 X-rays not done
866 only sign of pneumonia was convulsions or lethargy
141 refused investigation
96 died before X-ray
79 discharged home
69 no films available
73 machine dysfunction
89 other
603 reason unknown

2506 X-rays read

572 primary endpoint pneumonia
146 other infiltrate
1774 normal
14 uninterpretable

Figure 1: Flow chart showing the selection of patients for radiographs and
the reasons for missing radiographs

March, 2014) and at least one chest radiograph was
obtained from 2506 (55%). Radiographs were obtained
from 51% (1732 of 3373) of patients in the pre-vaccine
period and 67% (774 of 1149) in the post-vaccine period.
During the pre-vaccination period (ie, before Jan 1, 2011),
primary endpoint pneumonia was identified in 21%
(185 of 867) of readable radiograph images among children
aged 2–11 months, 26% (109 of 423) among children aged
12–23 months, 24% (79 of 327) among children
aged 24–59 months, and 34% (35 of 104) among children
aged 60–143 months.
Before imputation and modelling, the crude incidence
rates for radiologically-confirmed pneumonia among
e341
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Monthly incidence
Temporal trend and season
Temporal trend

Incidence per 100 000 person-years (log10 scale)

600

400

200

100

50
2006

2007

2008

2009

2010
Year

2011

2012

2013

2014

Figure 2: Monthly incidence of admission to Kilifi County Hospital among children aged 2–59 months with
WHO-defined radiologically-confirmed pneumonia and modelled predictions
The dashed lines show the transition period during which PCV10 was introduced among children younger than
5 years. The model excluded datapoints for December, 2012, and December, 2013, to account for two nurses’
strikes at Kilifi County Hospital.
IRR for PCV10
introduction

95% CI

p value

0·52

0·32–0·86

0·011

Age
2–59 months (primary
analysis)
2–11 months

0·73

0·39–1·36

0·324

12–23 months

0·54

0·27–1·10

0·091

0·50

0·24–1·01

0·052

0·89

0·47–1·69

0·724

24–59 months
60–143 months

Clinical severity (2–59 months only)
Severe pneumonia

0·56

0·30–1·06

0·077

Very severe pneumonia

0·52

0·28–0·96

0·038

Interrupted time series analysis adjusted for season (month of year) and study
time (months). IRRs=incidence rate ratios.

Table 2: IRRs for the effects of PCV10 introduction on admission to
hospital with radiologically-confirmed pneumonia among children
aged 2–143 months, by age subgroup and clinical severity

children aged 2–59 months were 180·9 (95% CI
163·0–200·2) per 100 000 person-years for the period
before PCV10 was introduced and 110·7 (93·3–130·3)
for the period after PCV10 introduction; the crude IRR
was 0·61 (0·50–0·74). In the interrupted time-series
model, which adjusted for season and time (figure 2,
table 2), the IRR for radiologically-confirmed pneumonia
associated with PCV10 introduction among children aged
2–59 months was 0·52 (0·32–0·86). The effect was
greatest among those aged 12–59 months. There was no
effect among children aged 60–143 months (table 2).
Radiologically-confirmed pneumonia varied substantially
by season, with a peak in November to January and a
trough in April to June (appendix). After accounting for
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season and the vaccine effect, the underlying incidence of
radiologically-confirmed pneumonia among children
2–59 months was stable over time (IRR per month 0·999,
0·990–1·007; appendix).
The annual incidence of admission with clinicallydefined pneumonia in 2002–03 was 2170 per 100 000 in
children aged 2–59 months; incidence of admission to
hospital significantly reduced across the study period by
0·5% per month (figure 3). Pneumonia admissions also
had marked seasonal variation, which closely followed
that of radiologically-confirmed pneumonia (appendix).
After adjusting for these factors, the IRR for admissions
with severe or very severe pneumonia associated with
introduction of the PCV10 programme was 0·73
(95% CI 0·54–0·97; table 3). Vaccine impact was greater
for severe pneumonia than for very severe pneumonia
(table 3). There was no evidence of benefit to children
aged 60–143 months.
There was no interaction between study time and
vaccine era in the analysis of the incidence of clinicallydefined pneumonia, nor of radiologically-confirmed
pneumonia among children aged 2–59 months. This
finding indicates that there was no further development
of indirect protection after the catch-up campaign.
After adjusting for seasonal variation and secular
trends, the modelled incidence rate of clinicallydefined pneumonia in December, 2010, was 1220 per
100 000 person-years among children aged 2–59 months;
for radiologically-confirmed pneumonia, this value was
301 per 100 000 person-years. By multiplying these
incidence rates against the vaccine effectiveness estimates
for clinically-defined and radiologically-confirmed pneu
monia, the reduction in disease incidence attributable to
vaccine introduction was 329 and 144 cases per 100 000
person-years, respectively.
The control condition—incidence of admission with
diarrhoea among children aged 2–59 months—was not
associated with PCV10 introduction (IRR 0·63, 95% CI
0·31–1·26; figure 3). However, in age-stratified analyses,
there was an association between PCV10 introduction
and incidence of diarrhoeal admissions in those aged
12–23 months (0·63, 0·41–0·99), 24–59 months (0·62,
0·39–0·99), and 60–143 months (0·66, 0·46–0·95; ap
pendix). The IRR among infants (0·79) was less extreme
than the IRRs seen in older age groups (0·62–0·66).
Truncating analysis time at the point when rotavirus
vaccination was introduced did not alter these findings.
We explored whether the observed effect of PCV10
on diarrhoea in some age groups suggested residual
confounding in patterns of hospital presentation. To
select a suitable control condition, we examined the
correlation between annual counts of admissions with
clinically-defined pneumonia in the pre-vaccine period
against annual counts of admissions with other
discharge diagnoses. The greatest correlations were
with unclassified discharges and with gastroenteritis,
although unclassified discharges were relatively
www.thelancet.com/lancetgh Vol 7 March 2019
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This interrupted time-series analysis of the rates of
hospital admission from a rolling cohort of about
43 000 children aged 2–59 months in Kilifi, Kenya,
suggests that the introduction of PCV10, with a
simultaneous catch-up campaign for children younger
than 5 years, was associated with a reduction in childhood
admissions to hospital with clinically-defined pneumonia
(by 27%) and radiologically-confirmed pneumonia
(by 48%). The vaccine reduced the incidence of admis
sion to hospital with clinically-defined pneumonia
(by 329 per 100 000 person-years) and radiologicallyconfirmed pneumonia (by 144 per 100 000 person-years).
There was no effect among children aged 5 years or older.
The observed effect in Kilifi was considerably greater
than the vaccine efficacy estimates from individually
randomised controlled trials of PCVs. Against severe
clinically-defined pneumonia, the vaccine efficacy of a
9-valent PCV was 12% (95% CI –9 to 29) in The Gambia3
and 17% (7 to 26) in South Africa.5 Against radiologicallyconfirmed pneumonia, the vaccine efficacies were 37%
in The Gambia3 and 20% in South Africa.8 In Bohol,
the Philippines, the point estimate for vaccine efficacy
of an 11-valent PCV against radiologically-confirmed
pneu
monia was 22·9% (–1·1 to 41·2); there was no
protection against clinically-defined pneumonia.4 A
randomised con
trolled trial9 of PCV10, done in
Argentina, Panama, and Colombia, estimated vaccine
efficacy against radiologically-confirmed pneumonia at
22·4%. These vaccine efficacy estimates, derived from
individually randomised trials, measure only the direct
protective effect of the vaccine, whereas the impact
estimates in the present study combine direct and
indirect effects. In the USA, the indirect effect of PCV7
against pneumonia was substantial;24 it is not surprising,
therefore, that the impact estimates in a real-world
implementation in Africa are considerably greater than
the efficacy estimates from trials.
There is relatively little information on the effect of
PCV elsewhere in tropical Africa. In a retrospective
analysis25 (2002–12) of clinically-defined pneumonia
among admission case-records from five district
hospitals in Rwanda, the impact of PCV7, introduced in
2009, was similar to that observed in Kilifi (vaccine
effectiveness 54%, 95% CI 42–63). However, a study of
the effect of PCV in children younger than 5 years in
The Gambia, comparing rates in the post-PCV13 era
(2014–15) with those in the pre-PCV7 era (2008–10),
found a 5–15% reduction in hospitalised clinicallydefined pneumonia, depending on age. For children
www.thelancet.com/lancetgh Vol 7 March 2019
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uncommon. The correlation with admission diagnosis
diarrhoea was greater yet (appendix). After adjusting for
log-transformed monthly rates of diarrhoea admissions,
instead of time in months, the IRR for clinically-defined
pneumonia associated with PCV10 in children aged
2–59 months was 0·83 (95% CI 0·54–1·28, table 3).
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Figure 3: Monthly incidence of admission to Kilifi County Hospital among children aged 2–59 months with
(A) clinically-defined pneumonia and (B) diarrhoea
Clinically-defined pneumonia includes severe or very severe pneumonia, according to WHO definitions.19
The dashed lines show the transition period during which PCV10 was introduced among children younger than
5 years. The model excluded datapoints for December, 2012, and December, 2013, to account for two nurses’
strikes at Kilifi County Hospital.

admitted to hospital with radiologically-confirmed
pneumonia, the reductions were 24–31%,10 which were
lower than the 37% estimate derived from a randomised
controlled trial3 of PCV9 in the same setting.
In Kilifi, across the 13-year study period, admission
incidence rates were consistently reduced, particularly
for malaria, malnutrition, and clinically-defined pneu
monia. Over the same period, mortality ratios in infants
and children younger than 5 years decreased sub
stantially, suggesting that changing admission rates
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Severe pneumonia
IRR

95% CI

Very severe pneumonia
p value

IRR

95% CI

All pneumonia
p value

IRR

95% CI

p value
0·033

Adjusted for time
2–59 months

0·60

0·40–0·91

0·017

0·87

0·56–1·34

0·519

0·73

0·54–0·97

2–11 months

0·66

0·41–1·07

0·090

0·73

0·48–1·11

0·143

0·70

0·50–1·00

0·048

12–23 months

0·61

0·39–0·94

0·027

1·28

0·83–1·96

0·264

0·84

0·61–1·15

0·283

24–59 months

0·59

0·37–0·92

0·020

0·78

0·40–1·54

0·479

0·71

0·43–1·19

0·192

0·93

0·62–1·39

0·721

0·96

0·61–1·50

0·857

0·95

0·56–1·59

0·832

60–143 months

Adjusted for diarrhoea admissions
2–59 months

0·95

0·60–1·51

0·818

0·74

0·36–1·51

0·405

0·83

0·54–1·28

0·399

0·91

0·55–1·48

0·697

0·72

0·43–1·21

0·219

0·86

0·60–1·24

0·428

12–23 months

1·07

0·64–1·77

0·804

1·32

0·69–2·53

0·408

1·10

0·71–1·71

0·681

24–59 months

0·76

0·46–1·27

0·299

0·68

0·32–1·43

0·308

0·76

0·43–1·33

0·334

1·14

0·41–3·18

0·795

0·51

0·25–1·06

0·072

0·61

0·18–2·05

0·427

2–11 months

60–143 months

Interrupted time-series analysis adjusted for season (month of year) and temporal trends (time in months or natural log-transformed monthly incidence rates of admission
with diarrhoea). We deseasonalised the log-diarrhoea series by subtracting trend-adjusted estimates for the effect of each month, and smoothed the series using locally
weighted scatterplot smoothing. IRRs=incidence rate ratios.

Table 3: IRRs for the effects of PCV10 introduction on admission to hospital with WHO-defined severe or very severe pneumonia among children aged
2–143 months

reflect a genuine improvement in health, rather than a
change in health-seeking behaviour. The effect of general
health trends on the incidence of clinically-defined
pneumonia in the pre-vaccine period was greater than
the effect of PCV10 introduction in 2011. Among children
aged 2–59 months, the annual incidence of clinicallydefined pneumonia per 100 000 children declined from
2170 in 2002–03 to 1220 in December, 2010; however,
with the introduction of PCV10, this incidence declined
further by 329. In other settings across Africa, which
have a higher baseline incidence than in Kenya, the
absolute benefits of PCV10 are probably considerably
greater. However, the full magnitude of the effect might
take longer in the absence of a catch-up campaign.
The observed effect of PCV10 against radiologicallyconfirmed pneumonia is substantially greater than that
against clinically-defined pneumonia, suggesting that
vaccine serotype pneumococci account for proportionately
more cases of radiologically-confirmed pneumonia than
of clinically-defined pneumonia. The WHO radiological
standard was developed to generate an endpoint that was
specific for bacterial pneumonia and, in the presence of a
vaccine programme for H influenzae type b, it is relatively
specific for pneumococcal pneumonia.3,6 However, as
well as differences in effect, we saw marked differences
in temporal trends; radiologically-confirmed pneu
monia was stable, whereas clinically-defined pneumonia
declined sharply with time. Clinical presentations of
pneumonia and malaria are difficult to distinguish26 and
the prevalence of malaria has declined sharply from
1999 to 2007,27 suggesting that some of the temporal
trends in clinically-defined pneumonia admissions might
be attributable to changes in malaria incidence.
We estimated the absolute reduction in admissions
with radiologically-confirmed pneumonia attributable to
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PCV10 introduction as 144 cases per 100 000 person-years.
Separately,20 we have evaluated the performance of the
study’s chest-radiograph readers in Kenya by comparing
their readings of 1179 images against the consensus
interpretation of three experienced consultant radio
logists in Oxford, UK. Although the specificity of the
local readers for radiologically-confirmed pneumonia
was high (0·95–0·96), the sensitivity was relatively low
(0·69–0·73).20 This disparity is unlikely to affect the
relative estimates of the effect of PCV10, expressed as
IRRs, but it does suggest that we underestimated the
absolute reduction in incidence of radiologicallyconfirmed pneumonia attributable to the vaccine
programme by about 30%.
Following the example of previous studies, we selected
diarrhoea as a control condition because it was common
and should be unaffected by PCV10.12 However, we
observed an unexpected decrease in diarrhoea admissions
among children 2–59 months associated with the timing
of PCV10 introduction (IRR 0·63, 95% CI 0·31–1·26).
We examined whether there was residual confounding in
the temporal pattern of hospital presentations by
adjusting for diarrhoea admissions, instead of time in
years. The point estimates for these incidence rate ratios
are consistent with the hypothesis that the vaccine is
protective, but the estimates lose statistical significance.
The decline in diarrhoeal admissions after PCV10
introduction is unlikely to be due to a biological effect of
PCV10. However, it might be a marker of another
intervention in this area that is targeting diarrhoea at the
same time as PCV10 introduction. The effect was
significant in all age groups beyond infancy and was
especially marked in those aged 5–11 years, who were too
old to be vaccinated with PCV10 (appendix). In 2007,
a campaign of community-led total sanitation was
www.thelancet.com/lancetgh Vol 7 March 2019
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introduced into Kilifi County to eliminate open
defecation by encouraging behaviour change and
building toilets. By 2012, 25% of the villages in Kilifi
County had this programme. It is possible that the
campaign had some effect on the incidence of diarrhoea
at the same time as PCV10 introduction. If so, the use of
diarrhoea as an adjustment variable for temporal trends
in hospital presentation would underestimate the true
effect of PCV10 against clinically-defined pneumonia.
Despite the ambiguity of the diarrhoea results, PCV10
had a large and significant effect on radiologically-con
firmed pneumonia in children younger than 5 years and
the temporally-adjusted impact estimates for severe
(IRR 0·60) and very severe clinically-defined pneumonia
(IRR 0·87) are consistent with this finding.
The reduction, by 27%, in admissions with clinicallydefined pneumonia implies that at least 27% of these
admissions were attributable to pneumococcal infections
of vaccine serotypes.28 As we inferred for radiologicallyconfirmed pneumonia, the greater effect of PCV10 on
severe versus very severe clinically-defined pneumonia
probably reflects the greater role of pneumococcus among
cases of severe pneumonia compared with very severe
pneumonia. Severe pneumonia was defined by lower
chest wall indrawing, which is a marker of poor lung
compliance during respiratory infection. Very severe
pneumonia was diagnosed by danger signs used in the
Integrated Management of Childhood Illness to define
very severe disease.19 Children with danger signs, which
included central cyanosis, inability to drink, convulsions,
lethargy, prostration, or unconsciousness, probably
include a reasonable proportion of admissions who have
febrile convulsions, malaria, sepsis, meningitis, and ence
phalitis. Few of these children would have had an aetiology
preventable by PCV10 and this observation might have
diluted the estimate of vaccine effect against very severe
clinically-defined pneumonia.
Several properties of the present study suggest that the
associations observed between vaccine introduction and
disease incidence were causal: the duration of surveillance
was long and the surveillance methods were consistent;
the vaccine programme was introduced with a rapid catchup campaign and nearly two-thirds of the target population
were given an immunising schedule at the same time
point; the analyses accounted for long-term trends in
disease incidence and seasonal variation; and the mag
nitude of the effects was large and therefore difficult to
attribute to incidental unobserved improvements in the
environment. In addition, these changes in the incidence
of pneumonia occurred simultaneously with a 64% reduc
tion in the prevalence of carriage of the serotypes included
in the vaccine29 and with a 68% decline in the incidence of
cases of invasive pneumococcal disease.30
Taken together, these factors suggest that the intro
duction of PCV10 in Kilifi, Kenya, has reduced the
incidence of admissions to hospital with clinically-defined
pneumonia by 27%, and of radiologically-confirmed
www.thelancet.com/lancetgh Vol 7 March 2019

pneumonia by 48%. Given that pneumonia, rather than
invasive pneumococcal disease, causes the greatest burden
of pneumococcal disease, these findings suggest that there
is a considerable improvement in child health associated
with the implementation of a PCV10 programme.
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